Clinical Trial

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2015-01-26; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2021-04-01
Status change: Recruiting → Not Yet Recruiting 2020-05-12
Status change: Active, Not Recruiting → Recruiting 2018-04-30
Status change: Recruiting → Active, Not Recruiting 2016-10-31
Status change: Not Yet Recruiting → Recruiting 2016-04-27
Trial Details
NCT Number NCT02347111
Lead Sponsor University of Illinois at Chicago
Collaborators: Medtronic
Conditions Atrial Fibrillation
Enrollment 162 participants
Start Date 2020-12-31
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-24